Ongoing clinical trials targeting OX40, CD27, and CD70 in cancer
| Target . | Agent . | Delivered with . | Trial number . | Tumor type . |
|---|---|---|---|---|
| OX40 | MEDI6469 (9B12) | Vaccine or adjuvant | NCT01644968 | Various advanced |
| Surgical resection | NCT02274155 | Head and neck | ||
| Surgical resection | NCT02559024 | Colorectal | ||
| Radiation | NCT01862900 | Breast | ||
| Radiotherapy and cyclophosphamide | NCT01303705 | Prostate | ||
| MEDI0562 | Monotherapy | NCT02318394 | Solid tumors | |
| Anti-CTLA-4 or anti-PD-L1 | NCT02705482 | Solid tumors | ||
| PF-04518600 | Alone or with anti-4-1BB | NCT02315066 | Solid tumors | |
| Anti-PD-L1 +/− anti-4-1BB | NCT02554812 | Solid tumors | ||
| Tyrosine-kinase inhibitor | NCT03092856 | Renal | ||
| INCAGN01949 | Alone | NCT02923349 | Solid tumors | |
| BMS-986178 | Alone or with anti-PD-1/anti-CTLA-4 | NCT02737475 | Solid tumors | |
| MOXR0916 (RG7888) | Alone | NCT02219724 | Solid tumors | |
| Anti-PD-L1 | NCT03029832 | Urothelial | ||
| Anti-PD-L1 +/− anti-VEGF | NCT02410512 | Solid tumors | ||
| GSK3174998 | Alone or with anti-PD-1 | NCT02528357 | Solid tumors | |
| MEDI6383 | Alone or with anti-PD-L1 | NCT02221960 | Solid tumors | |
| CD27 | Varlilumab (CDX-1127) | Alone | NCT01460134 | Hematologic or solid |
| Peptide vaccine and adjuvant | NCT02924038 | Glioma | ||
| Peptide vaccine | NCT02270372 | Ovarian and breast | ||
| Anti-PD-1 | NCT02335918 | Refractory | ||
| Anti-PD-1 | NCT03038672 | B-cell lymphoma | ||
| Antitumor mAb-drug conjugate | NCT02302339 | Melanoma | ||
| CD70 | SGN-CD70A | Alone | NCT02216890 | CD70+ renal or lymphoma |
| SGN-75 | Alone | NCT01015911 | CD70+ renal or NHL | |
| ARGX-110 | Alone | NCT01813539 | CD70+ advanced tumors | |
| Alone or with chemotherapy | NCT02759250 | Nasopharyngeal | ||
| MDX-1203 | Alone | NCT00944905 | CD70+ renal or NHL |
| Target . | Agent . | Delivered with . | Trial number . | Tumor type . |
|---|---|---|---|---|
| OX40 | MEDI6469 (9B12) | Vaccine or adjuvant | NCT01644968 | Various advanced |
| Surgical resection | NCT02274155 | Head and neck | ||
| Surgical resection | NCT02559024 | Colorectal | ||
| Radiation | NCT01862900 | Breast | ||
| Radiotherapy and cyclophosphamide | NCT01303705 | Prostate | ||
| MEDI0562 | Monotherapy | NCT02318394 | Solid tumors | |
| Anti-CTLA-4 or anti-PD-L1 | NCT02705482 | Solid tumors | ||
| PF-04518600 | Alone or with anti-4-1BB | NCT02315066 | Solid tumors | |
| Anti-PD-L1 +/− anti-4-1BB | NCT02554812 | Solid tumors | ||
| Tyrosine-kinase inhibitor | NCT03092856 | Renal | ||
| INCAGN01949 | Alone | NCT02923349 | Solid tumors | |
| BMS-986178 | Alone or with anti-PD-1/anti-CTLA-4 | NCT02737475 | Solid tumors | |
| MOXR0916 (RG7888) | Alone | NCT02219724 | Solid tumors | |
| Anti-PD-L1 | NCT03029832 | Urothelial | ||
| Anti-PD-L1 +/− anti-VEGF | NCT02410512 | Solid tumors | ||
| GSK3174998 | Alone or with anti-PD-1 | NCT02528357 | Solid tumors | |
| MEDI6383 | Alone or with anti-PD-L1 | NCT02221960 | Solid tumors | |
| CD27 | Varlilumab (CDX-1127) | Alone | NCT01460134 | Hematologic or solid |
| Peptide vaccine and adjuvant | NCT02924038 | Glioma | ||
| Peptide vaccine | NCT02270372 | Ovarian and breast | ||
| Anti-PD-1 | NCT02335918 | Refractory | ||
| Anti-PD-1 | NCT03038672 | B-cell lymphoma | ||
| Antitumor mAb-drug conjugate | NCT02302339 | Melanoma | ||
| CD70 | SGN-CD70A | Alone | NCT02216890 | CD70+ renal or lymphoma |
| SGN-75 | Alone | NCT01015911 | CD70+ renal or NHL | |
| ARGX-110 | Alone | NCT01813539 | CD70+ advanced tumors | |
| Alone or with chemotherapy | NCT02759250 | Nasopharyngeal | ||
| MDX-1203 | Alone | NCT00944905 | CD70+ renal or NHL |
NHL, non-Hodgkin lymphoma; VEGF, vascular endothelial growth factor.